Life Sciences

NOV 10, 2026

Kesmalea Therapeutics announces $60m series A financing to advance next-gen targeted protein degraders for alzheimer’s and other diseases and rebrands as Oyster Therapeutics

Deep Tech

NOV 05, 2026

FluoRok raises $30m (£22.8m) Series A to scale HF-free fluorochemical manufacturing

Life Sciences

NOV 05, 2026

Alethio Therapeutics raises $90 million (£67 million) in oversubscribed series A financing to advance a new generation of therapies for myeloproliferative neoplasms

Life Sciences

OCT 15, 2026

OMass Therapeutics announces $310 million Series C financing to advance portfolio of small molecule therapeutics in endocrinology and immunology

Deep Tech

OCT 14, 2026

Salience Labs secures $125 million in Series B funding to scale photonic networking chips for AI datacenter infrastructure

Life Sciences

OCT 13, 2026

Sitryx reports positive phase 1b results for first-in-class oral PKM2 modulator SYX-5219 in patients with moderate to severe atopic dermatitis

HealthTech

OCT 06, 2026

Sensible Biotechnologies secures $47 million to advance naturally modified mRNA platform and unlock next generation of mRNA medicines

Life Sciences

SEP 28, 2026

ONI achieves first-ever molecular resolution in a fully automated optical imaging workflow

Life Sciences

SEP 28, 2026

Beacon Therapeutics reports positive pivotal trial data for XLRP treatment

HealthTech

SEP 16, 2026

ReEmerge, Inc. exits stealth with oversubscribed $37m series A to challenge the limitations of chronic cognitive impairment caused by brain injuries

Deep Tech

SEP 16, 2026

Mixergy launches scheme that pays its hot water tank users for balancing the grid

Deep Tech

SEP 09, 2026

MCatalysis closes $5M seed round to produce low-carbon fuel below commodity cost

...
Oxford researchers & innovators
Working on cutting-edge research? Let’s explore its potential together.
Start the conversation
Shareholders
Interested in owning shares in OSE?
Contact our team
Co-investors
Ready to back Oxford’s most exciting spinouts?
Explore opportunities

WORK WITH US

Oxford researchers & innovators

Want your research to have real-world impact?

We partner with researchers and innovators across Oxford, Harwell and Culham to explore commercial potential, co-create ventures and build companies.

Start the conversation

Investors

Interested in becoming an OSE shareholder?

We’ve raised over £850m from global investors keen to access Oxford’s diverse, world-leading science. Our shareholders don’t just back OSE – many also co-invest alongside us.

Contact our team

Co-investors

Looking to invest in Oxford’s most exciting companies?

We partner with specialist global investors to fund and scale our companies – from pre-seed to growth. Together, OSE and our co-investors have invested more than £3bn.

Explore opportunities
OSE Manager Limited, a wholly owned subsidiary of Oxford Science Enterprises plc, is authorised and regulated by the Financial Conduct Authority.